BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $125
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.
BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.
